Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted ...
CURE

Bezuclastinib Submitted to FDA for Patients With Previously Treated GIST

FDA NDA submission for bezuclastinib targets post-imatinib GIST, using Real-Time Oncology Review and supported by prior ...
Medscape

NCCN Makes Many Changes to GIST Guidance; Presenter Identifies "$64 Million Question"

March 23, 2010 (Hollywood, Florida) — Whether or not to delay the use of imatinib mesylate (Gleevec, Novartis) in patients with localized gastrointestinal stromal tumors (GIST) after complete ...
Cure Today

What Patients With GIST Should Know About Their Disease

GIST Awareness Day underscores the need for continued research and patient education, with recent advancements in treatment and personalized therapy being crucial. Dr. Breelyn Wilky emphasizes the ...
EurekAlert!

New molecular classification of gastrointestinal stromal tumors guides precision treatment

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
ascopubs.org

Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).

The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST). Pathologic complete response and survival outcomes in patients with localized soft ...
ascopubs.org

Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway

Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical ...